BAKER BROS ADVISORS LLC Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Page: < prev 1 2 3 4 5 6 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 28 2020 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 1,335,362 | 0 | 11,638,314 | |
| Jul 28 2020 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 93,210 | 0 | 1,143,650 | |
| Jul 20 2020 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | P | 0.00 | 728,370 | 0 | 6,173,327 | |
| Jul 20 2020 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | P | 0.00 | 52,880 | 0 | 542,114 | |
| Jul 20 2020 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | P | 0.00 | 728,370 | 0 | 6,173,327 | |
| Jul 20 2020 | BCEL | Atreca, Inc. | BAKER BROS. ADVISORS LP | 10% Owner | Option Exercise | P | 0.00 | 52,880 | 0 | 542,114 | |
| Jul 17 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 14.23 | 13,589,904 | 193,395,206 | 18,840,379 | 5.3 M to 18.8 M (+258.83 %) |
| Jul 17 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 14.23 | 994,276 | 14,149,343 | 1,021,851 | 27.6 K to 1 M (+3,605.72 %) |
| Jul 06 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 223 | 0 | 2,883,650 | 2.9 M to 2.9 M (+0.01 %) |
| Jul 06 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 223 | 0 | 261,242 | 261 K to 261.2 K (+0.09 %) |
| Jul 02 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 294 | 0 | 29,313,492 | 29.3 M to 29.3 M (0.00 %) |
| Jul 02 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 294 | 0 | 2,849,725 | 2.8 M to 2.8 M (+0.01 %) |
| Jul 02 2020 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 25.48 | 37,520 | 956,010 | 37,520 | |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 52.73 | 11,158 | 588,361 | 11,158 | |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 6,118 | 0 | 38,440,095 | 38.4 M to 38.4 M (+0.02 %) |
| Jun 25 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 6,118 | 0 | 3,476,727 | 3.5 M to 3.5 M (+0.18 %) |
| Jun 19 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 13.42 | 90,766 | 1,218,080 | 90,766 | |
| Jun 10 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 62.50 | 4,135 | 258,438 | 4,135 | |
| May 28 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 98.68 | 10,514 | 1,037,522 | 10,514 | |
| May 28 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Buy | P | 102.55 | 1 | 103 | 29,313,198 | 29.3 M to 29.3 M (0.00 %) |
| May 28 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Buy | P | 102.55 | 1 | 103 | 2,849,431 | 2.8 M to 2.8 M (0.00 %) |
| May 28 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,282 | 0 | 29,313,197 | 29.3 M to 29.3 M (0.00 %) |
| May 28 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,282 | 0 | 2,849,430 | 2.8 M to 2.8 M (+0.05 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 160.33 | 3,171 | 508,406 | 3,171 | |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,335 | 0 | 43,290,171 | 43.3 M to 43.3 M (0.00 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,335 | 0 | 4,084,186 | 4.1 M to 4.1 M (+0.03 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 160.00 | 1,602,312 | 256,369,920 | 43,288,836 | 44.9 M to 43.3 M (-3.57 %) |
| May 19 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 160.00 | 147,688 | 23,630,080 | 4,082,851 | 4.2 M to 4.1 M (-3.49 %) |
| May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,189 | 0 | 7,846,213 | 7.8 M to 7.8 M (+0.02 %) |
| May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,189 | 0 | 998,953 | 997.8 K to 999 K (+0.12 %) |
| May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 3,468 | 0 | 7,845,024 | 7.8 M to 7.8 M (+0.04 %) |
| May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 3,468 | 0 | 997,764 | 994.3 K to 997.8 K (+0.35 %) |
| May 18 2020 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 1,465,603 | 0 | 10,302,952 | |
| May 18 2020 | KNSA | Kiniksa Pharmaceut ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 0.00 | 134,397 | 0 | 1,050,440 | |
| May 12 2020 | ZYME | Zymeworks Inc. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 35.49 | 9,000 | 319,410 | 9,000 | |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 158.50 | 457,803 | 72,561,776 | 44,891,148 | 45.3 M to 44.9 M (-1.01 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 158.50 | 42,197 | 6,688,225 | 4,230,539 | 4.3 M to 4.2 M (-0.99 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.16 | 4,343 | 721,610 | 45,348,951 | 45.4 M to 45.3 M (-0.01 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.16 | 400 | 66,462 | 4,272,736 | 4.3 M to 4.3 M (-0.01 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.96 | 48,880 | 8,063,118 | 45,353,294 | 45.4 M to 45.4 M (-0.11 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.96 | 4,505 | 743,133 | 4,273,136 | 4.3 M to 4.3 M (-0.11 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.19 | 84,663 | 13,901,157 | 45,402,174 | 45.5 M to 45.4 M (-0.19 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.19 | 7,805 | 1,281,534 | 4,277,641 | 4.3 M to 4.3 M (-0.18 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 163.41 | 16,159 | 2,640,610 | 45,486,837 | 45.5 M to 45.5 M (-0.04 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 163.41 | 1,489 | 243,324 | 4,285,446 | 4.3 M to 4.3 M (-0.03 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.62 | 41,072 | 6,843,564 | 45,502,996 | 45.5 M to 45.5 M (-0.09 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 166.62 | 3,786 | 630,837 | 4,286,935 | 4.3 M to 4.3 M (-0.09 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 165.70 | 91,613 | 15,180,641 | 45,544,068 | 45.6 M to 45.5 M (-0.20 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 165.70 | 8,444 | 1,399,205 | 4,290,721 | 4.3 M to 4.3 M (-0.20 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.60 | 178,862 | 29,440,041 | 45,635,681 | 45.8 M to 45.6 M (-0.39 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.60 | 16,485 | 2,713,372 | 4,299,165 | 4.3 M to 4.3 M (-0.38 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.06 | 45,606 | 7,482,107 | 45,814,543 | 45.9 M to 45.8 M (-0.10 %) |
| May 08 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 164.06 | 4,204 | 689,707 | 4,315,650 | 4.3 M to 4.3 M (-0.10 %) |
| May 07 2020 | NLTX | Neoleukin Therapeu ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 12.84 | 25,000 | 321,000 | 25,000 | |
| Apr 29 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 13.34 | 20,000 | 266,800 | 0 | |
| Apr 29 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 13.34 | 20,000 | 266,800 | 0 | |
| Apr 29 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Buy | M | 13.34 | 20,000 | 266,800 | 29,311,915 | 29.3 M to 29.3 M (+0.07 %) |
| Apr 29 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Buy | M | 13.34 | 20,000 | 266,800 | 2,848,148 | 2.8 M to 2.8 M (+0.71 %) |
| Apr 24 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 12.76 | 17,500 | 223,300 | 0 | |
| Apr 24 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Option Exercise | M | 12.76 | 17,500 | 223,300 | 0 | |
| Apr 24 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 12.76 | 17,500 | 223,300 | 45,860,149 | 45.8 M to 45.9 M (+0.04 %) |
| Apr 24 2020 | SGEN | SEATTLE GENETICS I ... | BAKER BROS. ADVISORS LP | Director | Buy | M | 12.76 | 17,500 | 223,300 | 4,319,854 | 4.3 M to 4.3 M (+0.41 %) |
| Apr 03 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 223 | 0 | 2,883,427 | 2.9 M to 2.9 M (+0.01 %) |
| Apr 03 2020 | IGMS | IGM Biosciences, I ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 223 | 0 | 261,019 | 260.8 K to 261 K (+0.09 %) |
| Apr 01 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 73.23 | 392 | 28,706 | 29,291,915 | 29.3 M to 29.3 M (0.00 %) |
| Apr 01 2020 | INCY | INCYTE CORP | BAKER BROS. ADVISORS LP | Director | Grant | A | 73.23 | 392 | 28,706 | 2,828,148 | 2.8 M to 2.8 M (+0.01 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 34.47 | 42,473 | 1,463,896 | 38,433,977 | 38.4 M to 38.4 M (+0.11 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 34.47 | 3,837 | 132,248 | 3,470,609 | 3.5 M to 3.5 M (+0.11 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.63 | 33,464 | 1,125,465 | 38,391,504 | 38.4 M to 38.4 M (+0.09 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.63 | 3,023 | 101,670 | 3,466,772 | 3.5 M to 3.5 M (+0.09 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.85 | 2,201 | 72,302 | 38,358,040 | 38.4 M to 38.4 M (+0.01 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.85 | 199 | 6,537 | 3,463,749 | 3.5 M to 3.5 M (+0.01 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.61 | 46,225 | 1,507,268 | 38,355,839 | 38.3 M to 38.4 M (+0.12 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.61 | 4,175 | 136,135 | 3,463,550 | 3.5 M to 3.5 M (+0.12 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.94 | 275 | 8,782 | 38,309,614 | 38.3 M to 38.3 M (0.00 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.94 | 25 | 798 | 3,459,375 | 3.5 M to 3.5 M (0.00 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.86 | 93,006 | 3,149,406 | 38,309,339 | 38.2 M to 38.3 M (+0.24 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 33.86 | 8,402 | 284,512 | 3,459,350 | 3.5 M to 3.5 M (+0.24 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.32 | 24,223 | 782,873 | 38,216,333 | 38.2 M to 38.2 M (+0.06 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.32 | 2,188 | 70,715 | 3,450,948 | 3.4 M to 3.5 M (+0.06 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.19 | 29,624 | 953,620 | 38,192,110 | 38.2 M to 38.2 M (+0.08 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.19 | 2,676 | 86,143 | 3,448,760 | 3.4 M to 3.4 M (+0.08 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.83 | 7,612 | 242,290 | 38,162,486 | 38.2 M to 38.2 M (+0.02 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.83 | 688 | 21,899 | 3,446,084 | 3.4 M to 3.4 M (+0.02 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.74 | 43,212 | 1,371,359 | 38,154,874 | 38.1 M to 38.2 M (+0.11 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.74 | 3,903 | 123,864 | 3,445,396 | 3.4 M to 3.4 M (+0.11 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.00 | 3,913 | 121,285 | 38,111,662 | 38.1 M to 38.1 M (+0.01 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.00 | 353 | 10,941 | 3,441,493 | 3.4 M to 3.4 M (+0.01 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.51 | 631,281 | 19,893,937 | 38,107,749 | 37.5 M to 38.1 M (+1.68 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.51 | 57,022 | 1,796,968 | 3,441,140 | 3.4 M to 3.4 M (+1.68 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.19 | 5,503 | 171,613 | 37,476,468 | 37.5 M to 37.5 M (+0.01 %) |
| Mar 18 2020 | ACAD | ACADIA PHARMACEUTI ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 31.19 | 497 | 15,499 | 3,384,118 | 3.4 M to 3.4 M (+0.01 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 38.38 | 9,172 | 352,019 | 10,602,550 | 10.6 M to 10.6 M (+0.09 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 38.38 | 828 | 31,778 | 971,988 | 971.2 K to 972 K (+0.09 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 37.75 | 6,237 | 235,433 | 10,593,378 | 10.6 M to 10.6 M (+0.06 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 37.75 | 563 | 21,252 | 971,160 | 970.6 K to 971.2 K (+0.06 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 36.69 | 17,058 | 625,914 | 10,587,141 | 10.6 M to 10.6 M (+0.16 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 36.69 | 1,542 | 56,581 | 970,597 | 969.1 K to 970.6 K (+0.16 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 38.99 | 9,172 | 357,570 | 10,570,083 | 10.6 M to 10.6 M (+0.09 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 38.99 | 828 | 32,280 | 969,055 | 968.2 K to 969.1 K (+0.09 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 39.97 | 95,934 | 3,834,588 | 10,560,911 | 10.5 M to 10.6 M (+0.92 %) |
| Mar 18 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 39.97 | 8,666 | 346,390 | 968,227 | 959.6 K to 968.2 K (+0.90 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 83.14 | 14,731 | 1,224,797 | 7,841,556 | 7.8 M to 7.8 M (+0.19 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 83.14 | 1,331 | 110,665 | 994,296 | 993 K to 994.3 K (+0.13 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.92 | 1,321 | 109,537 | 7,826,825 | 7.8 M to 7.8 M (+0.02 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.92 | 119 | 9,867 | 992,965 | 992.8 K to 993 K (+0.01 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.13 | 15,928 | 1,308,149 | 7,825,504 | 7.8 M to 7.8 M (+0.20 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.13 | 1,439 | 118,183 | 992,846 | 991.4 K to 992.8 K (+0.15 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.79 | 25,640 | 2,097,003 | 7,809,576 | 7.8 M to 7.8 M (+0.33 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.79 | 2,314 | 189,254 | 991,407 | 989.1 K to 991.4 K (+0.23 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.47 | 4,203 | 342,438 | 7,783,936 | 7.8 M to 7.8 M (+0.05 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.47 | 380 | 30,960 | 989,093 | 988.7 K to 989.1 K (+0.04 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.09 | 12,815 | 1,039,177 | 7,779,733 | 7.8 M to 7.8 M (+0.16 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.09 | 1,158 | 93,903 | 988,713 | 987.6 K to 988.7 K (+0.12 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 80.91 | 3,298 | 266,845 | 7,766,918 | 7.8 M to 7.8 M (+0.04 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 80.91 | 298 | 24,112 | 987,555 | 987.3 K to 987.6 K (+0.03 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.87 | 10,285 | 821,429 | 7,763,620 | 7.8 M to 7.8 M (+0.13 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.87 | 929 | 74,196 | 987,257 | 986.3 K to 987.3 K (+0.09 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.72 | 26,022 | 2,074,362 | 7,753,335 | 7.7 M to 7.8 M (+0.34 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.72 | 2,351 | 187,412 | 986,328 | 984 K to 986.3 K (+0.24 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.29 | 2,888 | 228,980 | 7,727,313 | 7.7 M to 7.7 M (+0.04 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.29 | 261 | 20,694 | 983,977 | 983.7 K to 984 K (+0.03 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.16 | 4,191 | 331,760 | 7,724,425 | 7.7 M to 7.7 M (+0.05 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.16 | 379 | 30,002 | 983,716 | 983.3 K to 983.7 K (+0.04 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 78.66 | 565 | 44,443 | 7,720,234 | 7.7 M to 7.7 M (+0.01 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 78.66 | 51 | 4,012 | 983,337 | 983.3 K to 983.3 K (+0.01 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.67 | 65,505 | 5,022,445 | 7,719,669 | 7.7 M to 7.7 M (+0.86 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.67 | 5,917 | 453,672 | 983,286 | 977.4 K to 983.3 K (+0.61 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.10 | 27,866 | 2,120,480 | 7,654,164 | 7.6 M to 7.7 M (+0.37 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.10 | 2,517 | 191,533 | 977,369 | 974.9 K to 977.4 K (+0.26 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.77 | 62,129 | 4,955,720 | 7,626,298 | 7.6 M to 7.6 M (+0.82 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.77 | 5,612 | 447,641 | 974,852 | 969.2 K to 974.9 K (+0.58 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.14 | 133,042 | 10,529,170 | 7,564,169 | 7.4 M to 7.6 M (+1.79 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.14 | 12,017 | 951,046 | 969,240 | 957.2 K to 969.2 K (+1.26 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.94 | 7,612 | 593,260 | 7,431,127 | 7.4 M to 7.4 M (+0.10 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.94 | 688 | 53,621 | 957,223 | 956.5 K to 957.2 K (+0.07 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.89 | 8,309 | 647,203 | 7,423,515 | 7.4 M to 7.4 M (+0.11 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.89 | 750 | 58,419 | 956,535 | 955.8 K to 956.5 K (+0.08 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 75.66 | 32,228 | 2,438,422 | 7,415,206 | 7.4 M to 7.4 M (+0.44 %) |
| Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 75.66 | 2,911 | 220,251 | 955,785 | 952.9 K to 955.8 K (+0.31 %) |
| Mar 16 2020 | ZYME | Zymeworks Inc. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 24.28 | 18,000 | 437,040 | 18,000 | |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.82 | 82,740 | 4,783,944 | 10,464,977 | 10.4 M to 10.5 M (+0.80 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.82 | 7,460 | 431,330 | 959,561 | 952.1 K to 959.6 K (+0.78 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 59.61 | 8,989 | 535,824 | 10,382,237 | 10.4 M to 10.4 M (+0.09 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 59.61 | 811 | 48,343 | 952,101 | 951.3 K to 952.1 K (+0.09 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 59.99 | 14,631 | 877,642 | 10,373,248 | 10.4 M to 10.4 M (+0.14 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 59.99 | 1,319 | 79,120 | 951,290 | 950 K to 951.3 K (+0.14 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.68 | 145,994 | 8,421,518 | 10,358,617 | 10.2 M to 10.4 M (+1.43 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.68 | 13,164 | 759,352 | 949,971 | 936.8 K to 950 K (+1.41 %) |
| Feb 26 2020 | KOD | Kodiak Sciences In ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 57.22 | 14,051 | 803,980 | 10,212,623 | 10.2 M to 10.2 M (+0.14 %) |